This is a very promising update for Asonep and Lpath, not that difficult to understand at all. So far Asonep has identified S1P as a key component and target supporting tumorigenesis in roughly a subset of RCC. Two patients going into 15 months is very impressive and promising. If the next cohort identifies and confirms one or more biomarkers identifying this patient tumor subset, this should set up he next series of studies which will be really interesting, notably in combination with established anticancer agents such as kinase inhibitors, or possibly with emerging immune modulators such as nivolumab, I know outside of Pfizer’s sphere but could if additive or synergistic, what is needed and where cancer therapy will succeed through knocking down subversion via immune pathways. S1P is implicated in many other cancers as a key component supporting aggressive disease, ovarian, pancreatic, HCC... I hope these early results can support a solid development program, good for all involved, Lpath, investors, and most notably the patients.
Gross manipulation on less than 15K shares? Looks like "business as usual" to me. There's always a chance people are updating their valuations and we get some recovery over the next few days but the more likely scenario is the crickets are still employed. 1Q15 or bust!